DexCom, Inc. (NASDAQ:DXCM) Receives $140.94 Average PT from Brokerages

DexCom, Inc. (NASDAQ:DXCMGet Free Report) has received a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $140.94.

Several research firms have issued reports on DXCM. Raymond James boosted their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Royal Bank of Canada started coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Citigroup increased their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Finally, Canaccord Genuity Group boosted their price objective on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th.

Check Out Our Latest Stock Report on DXCM

Insider Activity

In related news, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the transaction, the executive vice president now owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the sale, the director now owns 25,349 shares in the company, valued at $2,878,378.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the transaction, the executive vice president now owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The disclosure for this sale can be found here. Insiders have sold 57,700 shares of company stock worth $7,911,495 over the last three months. 0.30% of the stock is currently owned by corporate insiders.

Institutional Trading of DexCom

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Team Hewins LLC boosted its position in shares of DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after acquiring an additional 83 shares during the last quarter. Bleakley Financial Group LLC increased its position in DexCom by 1.3% during the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after purchasing an additional 87 shares during the last quarter. Stableford Capital II LLC raised its stake in DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after purchasing an additional 88 shares during the period. D Orazio & Associates Inc. boosted its holdings in shares of DexCom by 0.8% in the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after purchasing an additional 93 shares during the last quarter. Finally, Gulf International Bank UK Ltd grew its stake in shares of DexCom by 0.3% during the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after buying an additional 93 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 5.2 %

NASDAQ:DXCM opened at $110.57 on Friday. DexCom has a 12-month low of $74.75 and a 12-month high of $142.00. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The stock’s 50 day simple moving average is $124.81 and its 200-day simple moving average is $125.90. The firm has a market cap of $43.97 billion, a P/E ratio of 71.34, a PEG ratio of 2.84 and a beta of 1.22.

DexCom (NASDAQ:DXCMGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The company had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. Equities analysts anticipate that DexCom will post 1.78 EPS for the current year.

About DexCom

(Get Free Report

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

See Also

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.